Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9335071 | 0.95 | KMT2A (0.61) | KMT2AMEN1ALDH1A1PTK2BKDM4C | |
| SCHEMBL30658974 | 0.89 | KMT2A (0.52) | KMT2AMEN1ALDH1A1PTK2BKDM4C | |
| SCHEMBL31135557 | 0.89 | MEN1 (0.50) | KMT2AMEN1ALDH1A1KDM4CKDM4E | |
| SCHEMBL21818634 | 0.88 | KMT2A (0.51) | KMT2AMEN1ALDH1A1PTK2BKDM4C | |
| SCHEMBL14615145 | 0.88 | KMT2A (0.47) | KMT2AMEN1ALDH1A1PTK2BKDM4C | |
| SCHEMBL8295420 | 0.87 | ALDH1A1 (0.52) | KMT2AMEN1ALDH1A1KDM4CKDM4E | |
| SCHEMBL8297007 | 0.83 | MEN1 (0.54) | KMT2AMEN1ALDH1A1KDM4CKDM4E | |
| SCHEMBL8303231 | 0.83 | MEN1 (0.51) | KMT2AMEN1ALDH1A1KDM4CKDM4E | |
| SCHEMBL8296597 | 0.83 | MEN1 (0.51) | KMT2AMEN1ALDH1A1KDM4CKDM4E | |
| SCHEMBL8296601 | 0.83 | MEN1 (0.54) | KMT2AMEN1ALDH1A1KDM4CKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| EP-2106396-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | AstraZeneca AB (SE) | 2009-10-07 | — | — | EP | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20090035313-A1 | Compounds | PFIZER INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1651641-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-05-23 | — | — | EP | disclosed |
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005009965-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009995-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | KMT2A 3697/4885MEN1 2567/4885ALDH1A1 331/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | KMT2A 3697/4885MEN1 2567/4885ALDH1A1 331/4885 |
| US-20090035313-A1 | Compounds | NQO1, NAMPT, NNT | KMT2A 2721/4885MEN1 532/4885ALDH1A1 212/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | KMT2A 2669/4885MEN1 1966/4885ALDH1A1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.